Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €12.03 EUR
Change Today +0.335 / 2.87%
Volume 0.0
I76 On Other Exchanges
As of 2:10 AM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

ironwood pharmaceuticals inc (I76) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - €16.30
52 Week Low
09/17/14 - €8.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ironwood pharmaceuticals inc (I76) Related Businessweek News

No Related Businessweek News Found

ironwood pharmaceuticals inc (I76) Details

Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has collaboration agreements with Actavis plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, as well as in China, Hong Kong, and Macau. The company also has license agreements with Almirall, S.A. and Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Europe, as well as Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

464 Employees
Last Reported Date: 02/18/15
Founded in 1998

ironwood pharmaceuticals inc (I76) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $100.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $331.3K
Chief Scientific Officer, Senior Vice Preside...
Total Annual Compensation: $388.1K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $377.6K
Chief Legal Officer, Senior Vice President an...
Total Annual Compensation: $371.0K
Compensation as of Fiscal Year 2014.

ironwood pharmaceuticals inc (I76) Key Developments

Ironwood Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:40 PM

Ironwood Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Thomas Graney, Chief Financial Officer and Senior Vice President of Finance & Corporate Strategy.

Ironwood Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Announces Financial Guidance for the Year 2015

Ironwood Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter ended March 31, 2015, the company reported net loss was approximately $33,222,000, or $0.24 per basic and diluted share as compared to $49,626,000, or $0.38 per basic and diluted share, for the same period last year. Revenue was $28,932,000 compared to $14,605,000 for the same period last year. Loss from operations was $28,067,000 compared to $44,387,000 for the same period last year. The company ended the first quarter of 2015 with approximately $216 million of cash, cash equivalents and available-for-sale securities. Ironwood used approximately $36 million of cash for operations during the first quarter of 2015, as compared to approximately $58 million in the first quarter of 2014 and approximately $38 million in the fourth quarter of 2014, excluding the $15.0 million milestone payment received during the fourth quarter from Astellas upon initiation of a linaclotide Phase III IBS-C trial for Japan. The company announced its financial guidance for the year 2015. For the year, the company expects total operating expenses to be in the range of $220 million to $250 million, which includes $105 million to $120 million in R&D expenses and $115 million to $130 million in SG&A expenses. The company to expect combined actives and ironwood total 2015 marketing and sales expenses for LINZESS to be in the range of $230 million to $260 million.

Ironwood Pharmaceuticals, Inc. - Shareholder/Analyst Call



Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I76:GR €12.03 EUR +0.335

I76 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cumberland Pharmaceuticals Inc $6.93 USD -0.04
Nektar Therapeutics $11.74 USD -0.04
Progenics Pharmaceuticals Inc $5.88 USD +0.33
Sucampo Pharmaceuticals Inc $16.58 USD -0.50
Theravance Inc $16.83 USD +0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation I76 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.4x
Price/Book 28.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 17.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRONWOOD PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at